Date: 4 - 7 April 2017
Venue: Arena and Convention Centre, Liverpool
Presentations
Please view and download conference presentations by clicking on the links below:
Wednesday 5 April 2017
BHIVA Review Session
Translating recent research into clinical practice
Dr Matthew Page and Dr Steve Taylor, Birmingham Heartlands Hospital
Welcome Address by the Chair of the British HIV Association
Professor Chloe Orkin
Barts Health NHS Trust, London
BHIVA Invited Lecture 1
Travellers with HIV: what to take, what will you bring back?
Dr Philip Gothard, University College London Hospitals NHS Foundation Trust
BHIVA Lunchtime Workshop 1 - Clinico-pathological case presentations
A lump in the neck
Dr Emily Clarke, Solent NHS Trust, Portsmouth
A fortitudinous diagnosis in an HIV- positive man
Dr Stephanie Wilmore, Royal Free London NHS Foundation Trust
Light at the end of the tunnel
Dr Owen Seddon, University Hospital of Wales, Cardiff
BHIVA Lunchtime Workshop 2 - UK-CAB Workshop
NHS sustainability and transformation plans: financial restrictions and their effects on HIV clinical care
Professor Simon Barton, Chelsea and Westminster Hospital, London
NHS sustainability and transformation plans: financial restrictions and their effects on HIV clinical care
Dr JS Bamrah, British Medical Association
MRC Clinical Trials Unit Session
The motion: This house believes that efavirenz should remain as an option to treat HIV in the UK
For the motion: Dr Sarah Pett
MRC Clinical Trials Unit, London
Against the motion: Dr Alejandro Arenas-Pinto
MRC Clinical Trials Unit, London
Oral Research Presentations: Session 1: Antiretroviral Therapy
Abstract O1: Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients
Miss Amy Moore, Chelsea and Westminster Hospital NHS Foundation Trust, London
Abstract O2: Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir
Dr Joseph Custodio, Gilead Sciences Ltd
Abstract O3: Integrase inhibitor resistance in HIV-positive patients undergoing routine testing: frequency and clinical implications
Dr Daniela Kirwan, Public Health England
Abstract O4: Timing of detection of treatment-emergent resistance during rebound viraemia
Dr Nicola Mackie, Imperial College Healthcare NHS Trust, London
Abstract O5: Patient’s perceptions of switching from Atripla to generic Truvada and efavirenz
Dr Hardeep Kang, Blackpool Teaching Hospitals NHS Foundation Trust
Abstract O6: The next generiction update
Miss Venita Hardweir, Brighton and Sussex University Hospitals NHS Trust
BHIVA Plenary Session 1 - HIV training and the launch of the new internal medicine curriculum
Changes to postgraduate specialty training and the introduction of the new internal medicine curriculum
Dr Alastair Miller, Joint Royal Colleges of Physicians Training Board
HIV training in the dually accredited Internal Medicine and GUM curriculum
Dr Rak Nandwani, NHS Greater Glasgow and Clyde
The impact of the changes on common infection training
Professor Martin Wiselka, University Hospitals of Leicester NHS Trust
How those in training will be affected and what can be done to prepare for the future
Dr Emily Lord, Oxford University Hospitals NHS Foundation Trust
BHIVA Keynote Lecture
Towards elimination of HIV amongst gay and bisexual men in the United Kingdom
Dr Valerie Delpech, Public Health England
Towards elimination of HIV amongst gay and bisexual men in the United Kingdom
Dr Monica Desai, Public Health England
Welcome Reception